[go: up one dir, main page]

ATE115862T1 - Tocole als impfstoffadjuvans. - Google Patents

Tocole als impfstoffadjuvans.

Info

Publication number
ATE115862T1
ATE115862T1 AT90200127T AT90200127T ATE115862T1 AT E115862 T1 ATE115862 T1 AT E115862T1 AT 90200127 T AT90200127 T AT 90200127T AT 90200127 T AT90200127 T AT 90200127T AT E115862 T1 ATE115862 T1 AT E115862T1
Authority
AT
Austria
Prior art keywords
vaccines
tocole
vaccine adjuvant
adjuvant
tocols
Prior art date
Application number
AT90200127T
Other languages
English (en)
Inventor
Lammert Cornelius
Eric Onno Rijke
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE115862T1 publication Critical patent/ATE115862T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90200127T 1989-02-04 1990-01-18 Tocole als impfstoffadjuvans. ATE115862T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8900277 1989-02-04

Publications (1)

Publication Number Publication Date
ATE115862T1 true ATE115862T1 (de) 1995-01-15

Family

ID=19854075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90200127T ATE115862T1 (de) 1989-02-04 1990-01-18 Tocole als impfstoffadjuvans.

Country Status (15)

Country Link
US (2) US5650155A (de)
EP (1) EP0382271B1 (de)
JP (1) JP2892739B2 (de)
KR (1) KR0162646B1 (de)
CN (1) CN1056085C (de)
AT (1) ATE115862T1 (de)
AU (1) AU633043B2 (de)
CA (1) CA2008856C (de)
DE (1) DE69015222T2 (de)
DK (1) DK0382271T3 (de)
ES (1) ES2068989T3 (de)
GR (1) GR3015438T3 (de)
HU (1) HU206989B (de)
NZ (1) NZ232354A (de)
ZA (1) ZA90512B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
ATE403436T1 (de) * 1999-03-24 2008-08-15 Secr Defence Polykationische karbohydrate als immunostimulierende mittel in impstoffen
SI2266603T1 (sl) 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumorska cepiva
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
JP5041279B2 (ja) * 2004-04-22 2012-10-03 株式会社 Ｍｂｒ 細菌細胞壁骨格成分を含有する製剤
WO2006100111A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
PL1926496T3 (pl) * 2005-09-09 2014-02-28 Intervet Int Bv Szczepionka przeciw PCV-2
DK179025B1 (da) 2005-09-16 2017-08-28 Intervet Int Bv Fiskevaccine
EA014107B1 (ru) 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
EP2066344B2 (de) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inaktiviertes Poliovirus Mischimpfstoff
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2484375T3 (pl) 2006-09-26 2018-09-28 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
PT2167121E (pt) 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
EP2195021B1 (de) 2007-08-28 2012-02-29 Université de Liège Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
US7741418B2 (en) * 2007-12-31 2010-06-22 Bridgestone Corporation Process for producing polydienes
ES2553113T3 (es) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
RU2523561C2 (ru) * 2008-04-18 2014-07-20 Интервет Интернэшнл Б.В. Вакцина для защиты от lawsonia intracellularis
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
US8277814B2 (en) 2008-04-28 2012-10-02 Intervet International B.V. Avian Astrovirus
US20110280949A1 (en) * 2008-08-06 2011-11-17 Padma Malyala Microparticles for use in immunogenic compositions
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
JP5843615B2 (ja) 2009-02-06 2016-01-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
AU2010256461B2 (en) 2009-06-05 2016-03-17 Access To Advanced Health Institute Synthetic glucopyranosyl lipid adjuvants
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US9341623B2 (en) 2009-09-25 2016-05-17 Glaxosmithkline Biologicals Sa Immunodiffusion assay for influenza virus
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
JP2013522231A (ja) 2010-03-11 2013-06-13 イミューン デザイン コーポレイション インフルエンザのためのワクチン
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
EP2566958B1 (de) 2010-05-03 2015-12-30 GlaxoSmithKline Biologicals S.A. Verfahren zur inaktivierung des influenza-virus
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
BR112013008624B1 (pt) 2010-10-15 2022-07-26 Glaxosmithkline Biologicals S.A. Polipeptídeo gb de citomegalovírus (cmv), preparação, composição imunogênica, polinucleotídeo, vetor recombinante, e, microrganismo transgênico
HUE033739T2 (en) 2010-10-18 2018-01-29 Intervet Int Bv Turkey herpesvirus vector vaccine against avian influenza in poultry
MX344280B (es) 2010-12-14 2016-12-09 Glaxosmithkline Biologicals Sa Composicion antigenica de micobacteria.
EP2658568A1 (de) 2010-12-29 2013-11-06 Intervet International B.V. Impfstoffantigen von babesiose des hundes
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
AR087811A1 (es) 2011-09-08 2014-04-16 Umc Utrecht Holding Bv Vacuna contra el staphylococcus aureus
RU2662768C2 (ru) 2011-12-30 2018-07-31 Гесвал с.а. Рекомбинантный герпесвирус кои (khv) и вакцина для профилактики заболевания, вызываемого khv
AR089868A1 (es) 2012-02-03 2014-09-24 Animal Health Inst Vacuna vectorial de eimeria para campylobacter jejuni
HUE044841T2 (hu) 2012-02-07 2019-11-28 Infectious Disease Res Inst TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
LT3513806T (lt) 2012-12-05 2023-04-11 Glaxosmithkline Biologicals Sa Imunogeninė kompozicija
AU2014243149B2 (en) 2013-03-26 2017-11-23 The Pirbright Institute Stabilised FMDV capsids
WO2014154847A1 (en) 2013-03-29 2014-10-02 Intervet International B.V. Vaccine against rhipicephalus ticks
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
MY181007A (en) 2013-05-31 2020-12-15 Intervet Int Bv Scale drop disease (sdd) causative virus and derivatives thereof
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10392603B2 (en) 2013-08-30 2019-08-27 The Chemo-Sero-Therapeutic Research Institute Method of viral purification
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
MX2016009464A (es) 2014-01-21 2017-01-16 Immune Design Corp Composiciones para el uso en el tratamiento de afecciones alergicas.
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
HUE045936T2 (hu) 2014-06-25 2020-01-28 Glaxosmithkline Biologicals Sa Clostridium difficile immunogén készítmény
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
ES2721535T3 (es) 2014-12-16 2019-08-01 Glaxosmithkline Biologicals Sa Procedimiento de purificación de virus a gran escala
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
JP6931059B2 (ja) * 2016-12-23 2021-09-01 インターベット インターナショナル ベー． フェー． 豚用混合ワクチン
WO2018231706A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CA3067224A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
US11478541B2 (en) 2017-11-03 2022-10-25 Takeda Vaccines, Inc. Method for inactivating Zika virus and for determining the completeness of inactivation
EP3720488A1 (de) * 2017-12-04 2020-10-14 Intervet International B.V. Impfung mit replikonpartikeln und öladjuvanz
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
EP3843782A1 (de) 2018-08-29 2021-07-07 Centre Hospitalier Universitaire Vaudois (CHUV) Ebolaimpfstoffzusammensetzungen und verfahren zu ihrer verwendung
EP3662929A1 (de) 2018-12-07 2020-06-10 IDT Biologika GmbH Rekombinantes koi-herpesvirus (khv) und diva-impfstoff zur vorbeugung und/oder behandlung von khv-bedingten erkrankungen
WO2021013798A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP4161570A1 (de) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modifizierte spike-proteine des betacoronavirus
EP4188427A1 (de) 2020-08-03 2023-06-07 GlaxoSmithKline Biologicals S.A. Verkürztes fusobacterium nucleatum fusobacterium adhesin a (fada)-protein und immunogene zusammensetzungen davon
KR102617710B1 (ko) 2020-08-05 2024-01-25 주식회사 이노헨스 기판 처리장치
IL303334A (en) 2020-12-02 2023-07-01 Glaxosmithkline Biologicals Sa Donor strand complemented fimh
EP4032547A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce abgeleitete fragemente zur hsv therapie
WO2023072805A1 (en) 2021-10-25 2023-05-04 Intervet International B.V. A vaccine for the protection of piglets against swine influenza a virus infection
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
CN114984201A (zh) * 2022-04-24 2022-09-02 国药中生生物技术研究院有限公司 类天然脂滴纳米乳佐剂及其制备方法
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025032535A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
AU596581B2 (en) * 1986-04-15 1990-05-10 Sansho Seiyaku Co., Ltd. Topical agents for inhibiting the melanin generation
ZA872532B (en) * 1986-04-21 1987-11-25 Akzo Nv Combined vaccine
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines

Also Published As

Publication number Publication date
JP2892739B2 (ja) 1999-05-17
CA2008856A1 (en) 1990-08-04
JPH02250835A (ja) 1990-10-08
AU4897590A (en) 1990-08-09
HU900653D0 (en) 1990-04-28
DK0382271T3 (da) 1995-05-01
KR900012630A (ko) 1990-09-01
CN1056085C (zh) 2000-09-06
EP0382271B1 (de) 1994-12-21
CA2008856C (en) 2001-06-19
HUT56285A (en) 1991-08-28
US5667784A (en) 1997-09-16
ES2068989T3 (es) 1995-05-01
EP0382271A1 (de) 1990-08-16
CN1044594A (zh) 1990-08-15
AU633043B2 (en) 1993-01-21
DE69015222T2 (de) 1995-05-04
HU206989B (en) 1993-03-01
ZA90512B (en) 1990-11-28
KR0162646B1 (ko) 1998-12-01
DE69015222D1 (de) 1995-02-02
NZ232354A (en) 1991-09-25
GR3015438T3 (en) 1995-06-30
US5650155A (en) 1997-07-22

Similar Documents

Publication Publication Date Title
DE69015222D1 (de) Tocole als Impfstoffadjuvans.
LU91486I2 (fr) Emulsion huile-dans-eau comprenant du squalène, duDL-a-tocophérol et du polysorbate 80
ATE95425T1 (de) Impfstofformulierung.
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
DK1149589T3 (da) Proteinadjuvanser
ATE142110T1 (de) Impfstoff adjuvans
FI925835A0 (fi) Vacciner innehaollande liposomer
DE3689478D1 (de) Teilchenförmiges emulgierbares haarkonditioniermittel.
ES2034188T3 (es) Composiciones cosmeticas.
ATE149091T1 (de) Einen tetra-polyol enthaltendes impfstoff- adjuvans
NL300186I1 (nl) Acellulair vaccin.
IT9012431A0 (it) Dispositivo per il collegamento amovibile di due mobili per sedersi disposti affiancati
SU1713152A1 (ru) Адъювант для ящурной вакцины
IT1123773B (it) Dispositivo di giunzione per il collegamento di elementi lastriformi,utilizzabile per la realizzazione di tavoli,scrivanie e simili

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time